Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential
- PMID: 15576322
- DOI: 10.1515/BC.2004.133
Secretory leukoprotease inhibitor and pulmonary surfactant serve as principal defenses against influenza A virus infection in the airway and chemical agents up-regulating their levels may have therapeutic potential
Abstract
Influenza A virus (IAV) is one of the most common infectious pathogens in humans. Entry of this virus into cells is primarily determined by host cellular trypsin-type processing proteases, which proteolytically activate viral membrane fusion glycoprotein precursors. Human IAV and murine parainfluenza virus type 1 Sendai virus are exclusively pneumotropic, and the infectious organ tropism of these viruses is determined by the susceptibility of the viral envelope glycoprotein to cleavage by proteases in the airway. Proteases in the upper respiratory tract are suppressed by secretory leukoprotease inhibitor, and those in the lower respiratory tract are suppressed by pulmonary surfactant, which by adsorption inhibits the interaction between the proteases and viral membrane proteins. Although the protease activities are predominant over the activities of inhibitory compounds under normal airway conditions, intranasal administration of inhibitors was able to significantly suppress multi-cycles of viral replication in the airway. In addition, we identified chemical agents that could act as defensive factors by up-regulating the levels of the natural inhibitors and immunoglobulin A (IgA) in airway fluids. One of these compounds, ambroxol, is a mucolytic and anti-oxidant agent that stimulates the release of secretory leukoprotease inhibitor and pulmonary surfactant in the early phase, and IgA in the late phase of infection at an optimal dose, i.e. a dose sufficient to inhibit virus proliferation and increase the survival rate of animals after treatment with a lethal dose of IAV. Another agent, clarithromycin, is a macrolide antibiotic that increases IgA levels through augmentation of interleukin-12 levels and mucosal immunization in the airway. In addition to the sialidase inhibitors, which prevent the release of IAV from infected cells, inhibitors of the processing proteases and chemical agents that augment mucosal immunity and/or levels of the relevant defensive compounds may also ultimately prove to be useful as new anti-influenza agents.
Similar articles
-
Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells.J Pharmacol Exp Ther. 2010 Apr;333(1):81-90. doi: 10.1124/jpet.109.162149. Epub 2009 Dec 29. J Pharmacol Exp Ther. 2010. PMID: 20040578
-
Proteases essential for human influenza virus entry into cells and their inhibitors as potential therapeutic agents.Curr Pharm Des. 2007;13(4):405-14. doi: 10.2174/138161207780162971. Curr Pharm Des. 2007. PMID: 17311557 Review.
-
Defense mechanisms against influenza virus infection in the respiratory tract mucosa.Jpn J Infect Dis. 2004 Dec;57(6):236-47. Jpn J Infect Dis. 2004. PMID: 15623947 Review.
-
The human mucus protease inhibitor and its mutants are novel defensive compounds against infection with influenza A and Sendai viruses.Biopolymers. 1999;51(1):79-86. doi: 10.1002/(SICI)1097-0282(1999)51:1<79::AID-BIP9>3.0.CO;2-W. Biopolymers. 1999. PMID: 10380355
-
Cellular proteases involved in the pathogenicity of enveloped animal viruses, human immunodeficiency virus, influenza virus A and Sendai virus.Adv Enzyme Regul. 1996;36:325-47. doi: 10.1016/0065-2571(95)00016-x. Adv Enzyme Regul. 1996. PMID: 8869754
Cited by
-
Restriction of Viral Glycoprotein Maturation by Cellular Protease Inhibitors.Viruses. 2024 Feb 22;16(3):332. doi: 10.3390/v16030332. Viruses. 2024. PMID: 38543698 Free PMC article. Review.
-
Ambroxol for the treatment of COVID-19 among hospitalized patients: A multicenter retrospective cohort study.Front Microbiol. 2022 Oct 6;13:1013038. doi: 10.3389/fmicb.2022.1013038. eCollection 2022. Front Microbiol. 2022. PMID: 36274736 Free PMC article.
-
SPINK6 inhibits human airway serine proteases and restricts influenza virus activation.EMBO Mol Med. 2022 Jan 11;14(1):e14485. doi: 10.15252/emmm.202114485. Epub 2021 Nov 26. EMBO Mol Med. 2022. PMID: 34826211 Free PMC article.
-
The past, present and future of RNA respiratory viruses: influenza and coronaviruses.Pathog Dis. 2020 Oct 7;78(7):ftaa046. doi: 10.1093/femspd/ftaa046. Pathog Dis. 2020. PMID: 32860686 Free PMC article. Review.
-
Regulation and activity of secretory leukoprotease inhibitor (SLPI) is altered in smokers.Am J Physiol Lung Cell Mol Physiol. 2014 Feb;306(3):L269-76. doi: 10.1152/ajplung.00290.2013. Epub 2013 Nov 27. Am J Physiol Lung Cell Mol Physiol. 2014. PMID: 24285265 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous